Challenges With Treating Asymptomatic RAI-Refractory Differentiated Thyroid Cancer
Marcia Brose, MD, PhD discusses the key unanswered questions oncologists have for treating patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer.
Marcia Brose, MD, PhD a medical oncologist at Penn Medicine, discusses the key unanswered questions oncologists have for treating patients with asymptomatic radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
In the field, there is a plethora of data around sorafenib (Nexavar) and lenvatinib (Lenvima), which are based on large phase 2 clinical trials performed for patients with RAI-refractory DTC that is growing. The population is broad, and it is difficult to understand which patients are actively progressing and which are more indolently progressing, says Brose. Determining when to start therapy for these patients is the key challenge, she adds.
A potential strategy for answering the question, Brose states, is to start therapy immediately for some patients and wait for others. Then, Brose explains, oncologists will be able to determine whether there was a difference in patients’ performance on the drug based on the time to initiation of treatment.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
